Management of Severe Preeclampsia

Clinical Presentation and Diagnosis

The American College of Obstetricians and Gynecologists recommends that patients with severe preeclampsia, characterized by severe hypertension (≥160/105 mmHg) and neurological symptoms (such as severe headache), should receive immediate magnesium sulfate administration for seizure prophylaxis 1, 2
Severe preeclampsia is diagnosed based on the presence of severe hypertension and symptoms such as severe headache, renal dysfunction (elevated creatinine levels), and significant proteinuria 3, 4

Immediate Management

The American Heart Association recommends that magnesium sulfate should be administered immediately for seizure prophylaxis in patients with severe preeclampsia, with a loading dose of 4-5g IV over 5 minutes, followed by a maintenance dose of 1-2g/hour continuous IV infusion 1
The European Society of Cardiology recommends that blood pressure should be controlled urgently in a monitored setting, with a target diastolic blood pressure of 85 mmHg and systolic blood pressure of 110-140 mmHg 5, 2
The American College of Obstetricians and Gynecologists recommends that first-line IV antihypertensive options include labetalol, nicardipine, and hydralazine, with careful monitoring of blood pressure and fetal status 3, 4, 1

Preparation for Delivery

The American College of Obstetricians and Gynecologists recommends that delivery should be planned after maternal stabilization with magnesium sulfate and blood pressure control, and that vaginal delivery is preferred unless cesarean is indicated for obstetric reasons 6, 3, 5
The European Society of Cardiology recommends that indications for immediate delivery include severe headache, deteriorating renal function, and gestational age ≥34 weeks 1, 5

Critical Monitoring Requirements

The American College of Obstetricians and Gynecologists recommends that continuous maternal monitoring should include blood pressure, deep tendon reflexes, respiratory rate, urine output, and oxygen saturation 1, 2
The European Society of Cardiology recommends that laboratory monitoring should include complete blood count, liver enzymes, and creatinine levels, and that fetal monitoring should include continuous fetal heart rate monitoring and ultrasound assessment of fetal status 5, 2

Management of Severe Preeclampsia

Immediate Stabilization

The American College of Cardiology recommends initiating urgent antihypertensive therapy immediately in patients with severe hypertension, with a target blood pressure of systolic 110-140 mmHg and diastolic 85 mmHg to reduce the risk of maternal cerebral hemorrhage while maintaining uteroplacental perfusion in patients with severe preeclampsia 7, 8
The European Society of Cardiology suggests that the target blood pressure should be achieved to prevent maternal complications, with a threshold of ≥160/110 mmHg for severe hypertension, and quantifying proteinuria using spot urine protein/creatinine ratio to confirm significant proteinuria 7, 8

Comprehensive Maternal Assessment

The European Heart Journal recommends a complete blood count, comprehensive metabolic panel, and peripheral blood smear to assess for hemolysis, elevated liver enzymes, and low platelets, with a hemoglobin level suggesting HELLP syndrome or severe disease, and a creatinine level at the upper limit of normal but concerning in pregnancy 8
The American College of Obstetricians and Gynecologists suggests quantifying proteinuria using spot urine protein/creatinine ratio, with a ratio of ≥30 mg/mmol confirming significant proteinuria, and repeating labs at least twice weekly or more frequently if clinical deterioration occurs 7, 8

Medications to Avoid

The European Heart Journal states that ACE inhibitors, ARBs, and direct renin inhibitors are absolutely contraindicated due to severe fetotoxicity, and diuretics are contraindicated as they further reduce plasma volume 8

Management of Severe Pre-eclampsia

Immediate Management

The American College of Obstetricians and Gynecologists recommends immediate administration of magnesium sulfate for seizure prophylaxis and aggressive blood pressure control with IV antihypertensives in patients with severe pre-eclampsia, followed by expedited delivery after maternal stabilization 9, 10
The American Society of Anesthesiologists suggests that magnesium sulfate must be administered immediately to all patients with severe pre-eclampsia who have at least one clinical sign of seriousness to prevent progression to eclampsia 9, 10
Initiate IV antihypertensive therapy immediately when systolic BP ≥160 mmHg and/or diastolic BP ≥110 mmHg persisting for more than 15 minutes, as recommended by the American Heart Association 9, 10

Transfer and Coordination

The American College of Obstetricians and Gynecologists recommends that medicalised transport to a specialized obstetric center should be systematically considered for all patients with severe pre-eclampsia 9, 10
Before transfer, coordinate with obstetric and anesthetic-intensivist teams at receiving facility via phone, discuss antihypertensive treatment initiation and modalities, involve emergency medical assistance service regulating doctor, and initiate magnesium sulfate and blood pressure control prior to transport, as suggested by the Society for Obstetric Anesthesia and Perinatology 9

Pre-Eclampsia Management

Definition and Recognition

Epigastric or right upper quadrant pain is a symptom of severe pre-eclampsia, suggesting hepatic capsule distension or HELLP syndrome, in patients with hypertension and proteinuria, according to the British Medical Journal 11, 12
Renal dysfunction, characterized by oliguria and elevated creatinine, is a criterion for severe pre-eclampsia, as stated by the British Journal of Anaesthesia 13
Thrombocytopenia and elevated liver enzymes are indicators of HELLP syndrome, a severe variant of pre-eclampsia, as reported by the British Journal of Anaesthesia and the British Medical Journal 12, 13

Immediate Management

The British Journal of Anaesthesia recommends monitoring urine output hourly via Foley catheter, with a target of ≥100 mL/4 hours, in patients with severe pre-eclampsia receiving magnesium sulfate 13
Deep tendon reflexes should be assessed before each magnesium dose to monitor for toxicity, as advised by the British Journal of Anaesthesia 13
Respiratory rate should be monitored to detect magnesium toxicity, which can cause respiratory depression, according to the British Journal of Anaesthesia 13

HELLP Syndrome Recognition

The British Journal of Anaesthesia defines HELLP syndrome by the presence of hemolysis, elevated liver enzymes, and low platelets, with a maternal mortality rate of 3.4% 13
Epigastric or right upper quadrant pain is a hallmark symptom of HELLP syndrome, as reported by the British Medical Journal and the British Journal of Anaesthesia 11, 13
Severe hypoglycemia can occur in patients with HELLP syndrome, and glucose should be monitored intraoperatively, as stated by the British Journal of Anaesthesia 13

Critical Considerations

The average interval from diagnosis to delivery in patients with pre-eclampsia at <32 weeks is 14 days, but some may require delivery within 72 hours, as reported by the British Medical Journal 11, 12
Placental abruption is an indication for immediate delivery, regardless of gestational age, as stated by the British Medical Journal 12

Management of Severe Preeclampsia

Immediate Stabilization

The American College of Cardiology recommends severe preeclampsia requires immediate dual therapy with intravenous magnesium sulfate for seizure prophylaxis and aggressive blood pressure control with IV labetalol, followed by expedited delivery after maternal stabilization 14
Administer magnesium sulfate immediately for all patients with severe preeclampsia or those with neurological symptoms 14
Initiate IV antihypertensive therapy immediately when BP ≥160/110 mmHg persists for more than 15 minutes 14
First-line agent: IV labetalol, with dosing: 20mg IV bolus, then 40mg after 10 minutes, followed by 80mg every 10 minutes to maximum 220mg 15
Target BP: Systolic 110-140 mmHg and diastolic 85 mmHg (or at minimum <160/105 mmHg) 15, 14
The goal is to decrease mean BP by 15-25% to prevent maternal cerebral hemorrhage while maintaining uteroplacental perfusion 15
Short-acting oral nifedipine should be avoided, especially when combined with magnesium sulfate, due to risk of uncontrolled hypotension and fetal compromise 15
Sodium nitroprusside should only be used as last resort for extreme emergencies due to risk of fetal cyanide poisoning 15

Critical Monitoring Requirements

Hourly urine output via Foley catheter with target ≥100 mL/4 hours (or >35 mL/hour) 15
Oxygen saturation on room air (maternal early warning if <95%) 15
Assess for maternal agitation, confusion, or unresponsiveness 15
Monitor for non-remitting headache and shortness of breath 15
Obtain at least twice weekly (or more frequently with clinical deterioration): hemoglobin, platelet count, liver transaminases, creatinine, and uric acid 14
Ultrasound assessment at diagnosis: fetal biometry, amniotic fluid, and umbilical artery Doppler 14
Repeat ultrasound every 2 weeks if initial assessment normal, more frequently if fetal growth restriction present 14

Delivery Timing

Deliver immediately after maternal stabilization for gestational age ≥37 weeks 14
Induction of labor is associated with improved maternal outcome 15
Expectant conservative management is appropriate if maternal and fetal status stable for gestational age 34-37 weeks 14
Deliver if any maternal or fetal deterioration occurs for gestational age 34-37 weeks 14
Conservative expectant management at a center with Maternal-Fetal Medicine expertise for gestational age <34 weeks 14
Inability to control BP despite ≥3 classes of antihypertensives in appropriate doses is an absolute indication for immediate delivery 14
Progressive thrombocytopenia or progressively abnormal liver/renal function tests is an absolute indication for immediate delivery 14
Pulmonary edema is an absolute indication for immediate delivery 14
Severe intractable headache, repeated visual scotomata, or convulsions is an absolute indication for immediate delivery 14
Non-reassuring fetal status is an absolute indication for immediate delivery 14
Maternal pulse oximetry deterioration is an absolute indication for immediate delivery 14

Special Considerations

Drug of choice for pulmonary edema: IV nitroglycerin (glycerol trinitrate) starting at 5 mcg/min, gradually increased every 3-5 minutes to maximum 100 mcg/min 15
Plasma volume expansion is not recommended routinely for pulmonary edema 14
Do not attempt to diagnose "mild versus severe" preeclampsia clinically—all cases may become emergencies rapidly 14
Do not use serum uric acid or level of proteinuria as indication for delivery 14
Do not reduce antihypertensives if diastolic BP falls <80 mmHg 14
For gestational age <24 weeks, expectant management is associated with high maternal morbidity with limited perinatal benefit—counsel regarding pregnancy termination 14

Management of Severe Hypertension and Non‑Reassuring Fetal Status at Term

Immediate Stabilization (Maternal)

Urgent treatment of severe hypertension (≥ 160/110 mm Hg) within 30–60 minutes is recommended to prevent maternal stroke or cerebral hemorrhage. 16
Intravenous labetalol is a first‑line agent (initial 20 mg bolus, repeat 40 mg after 10 min, then 80 mg every 10 min up to a maximum of 220 mg). If labetalol is unavailable, IV hydralazine may be used, and oral immediate‑release nifedipine is an acceptable alternative. 16
Target blood pressure after treatment: systolic 110–140 mm Hg and diastolic ≈ 85 mm Hg (with a minimum goal of < 160/105 mm Hg). 16
Magnesium sulfate should be started immediately for any patient with severe hypertension and preeclampsia to prevent eclamptic seizures. 16

Delivery Decision

Gestational age ≥ 37 weeks combined with preeclampsia constitutes an absolute indication for delivery, regardless of other factors. 17
A non‑reassuring fetal heart‑rate pattern (Category II) is also an absolute indication for delivery in this setting. 17

Maternal Monitoring During Stabilization

Continuous blood‑pressure monitoring should be maintained until the patient is hemodynamically stable. 16

Laboratory and Fetal Assessment

Obtain immediate laboratory studies including a complete blood count (platelet count), liver transaminases, serum creatinine, and uric acid to evaluate for preeclampsia‑related organ dysfunction. 17
Perform bedside ultrasound to assess fetal biometry, amniotic‑fluid volume, and umbilical‑artery Doppler flow as part of fetal surveillance. 17

Post‑Delivery Management

After delivery, methyldopa should be replaced with an alternative antihypertensive agent if it was used during pregnancy. 18
Blood‑pressure monitoring should continue at least every 4 hours while the patient is awake for a minimum of three days postpartum, because hypertension can worsen between days 3–6 after delivery. 18

All statements are supported by the cited references.

Management of Severe Preeclampsia with Fetal Distress

Magnesium Sulfate for Seizure Prophylaxis

Magnesium sulfate reduces the risk of progression to eclampsia by roughly 50 % in women with severe preeclampsia 19

Antihypertensive Therapy

First‑Line and Alternative IV Agents

Intravenous labetalol is recommended as the first‑line agent for rapid blood‑pressure reduction in severe preeclampsia 20
If labetalol is contraindicated or unavailable, intravenous hydralazine or nicardipine may be used as alternative agents 20

Blood‑Pressure Targets and Delivery Requirement

When systolic/diastolic pressure reaches ≥ 160/110 mm Hg in severe preeclampsia, delivery should be performed after maternal stabilization 20
During labor and delivery, antihypertensive therapy should be continued to maintain systolic < 160 mm Hg and diastolic < 110 mm Hg 20

Medications to Avoid

Short‑acting oral nifedipine should be avoided, especially in combination with magnesium sulfate, because of the risk of uncontrolled hypotension and fetal compromise 20
Sodium nitroprusside is reserved for extreme emergencies only, due to the potential for fetal cyanide and thiocyanate toxicity when used for more than 4 hours 20

Delivery Planning

Mode of Delivery

Vaginal delivery is the preferred route for women with severe preeclampsia unless obstetric indications (e.g., fetal distress, placental abruption) mandate cesarean delivery 20

Intra‑operative Blood‑Pressure Management

Antihypertensive infusions should be maintained throughout the operative period to keep systolic < 160 mm Hg and diastolic < 110 mm Hg, thereby protecting maternal cerebral circulation while preserving uteroplacental perfusion 20